{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:08:40Z","timestamp":1776701320349,"version":"3.51.2"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s13555-024-01172-6","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T15:02:08Z","timestamp":1716562928000},"page":"1575-1585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment Discontinuation in Patients with Psoriasis Treated with Biologics: A Retrospective Analysis of German Health Claims Data"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"Andreas","family":"Pinter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina C.","family":"Manz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Mocek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"H\u00f6er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"1172_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1\u201310. https:\/\/doi.org\/10.1007\/s00403-010-1080-1.","journal-title":"Arch Dermatol Res"},{"key":"1172_CR2","doi-asserted-by":"publisher","first-page":"A566","DOI":"10.1016\/j.jval.2016.09.1269","volume":"19","author":"C Jacob","year":"2016","unstructured":"Jacob C, Meier F, Neidhardt K, et al. Epidemiology and costs of psoriasis in Germany\u2014a retrospective claims data analysis. Value Health. 2016;19:A566. https:\/\/doi.org\/10.1016\/j.jval.2016.09.1269.","journal-title":"Value Health"},{"key":"1172_CR3","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https:\/\/doi.org\/10.1136\/bmj.m1590.","journal-title":"BMJ"},{"key":"1172_CR4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34:2461\u201398. https:\/\/doi.org\/10.1111\/jdv.16915.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1172_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub3","author":"E Sbidian","year":"2020","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1172_CR6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1590\/abd1806-4841.20175603","volume":"92","author":"J Vide","year":"2017","unstructured":"Vide J, Magina S. Moderate to severe psoriasis treatment challenges through the era of biological drugs. An Bras Dermatol. 2017;92:668\u201374. https:\/\/doi.org\/10.1590\/abd1806-4841.20175603.","journal-title":"An Bras Dermatol"},{"key":"1172_CR7","doi-asserted-by":"publisher","first-page":"e33486","DOI":"10.1371\/journal.pone.0033486","volume":"7","author":"EA Brezinski","year":"2012","unstructured":"Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS ONE. 2012;7:e33486. https:\/\/doi.org\/10.1371\/journal.pone.0033486.","journal-title":"PLoS ONE"},{"key":"1172_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"key":"1172_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3109\/09546634.2012.755255","volume":"24","author":"M Bonafede","year":"2013","unstructured":"Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatolog Treat. 2013;24:369\u201373. https:\/\/doi.org\/10.3109\/09546634.2012.755255.","journal-title":"J Dermatolog Treat"},{"key":"1172_CR10","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/bjd.13087","volume":"171","author":"JMPA van den Reek","year":"2014","unstructured":"van den Reek JMPA, Zweegers J, Kievit W, et al. \u201cHappy\u201d drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol. 2014;171:1189\u201396. https:\/\/doi.org\/10.1111\/bjd.13087.","journal-title":"Br J Dermatol"},{"key":"1172_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","volume":"206","author":"M Ludwig","year":"2022","unstructured":"Ludwig M, Enders D, Basedow F, Walker J, Jacob J. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health. 2022;206:57\u201362. https:\/\/doi.org\/10.1016\/j.puhe.2022.02.013.","journal-title":"Public Health"},{"key":"1172_CR12","unstructured":"Federal Institute for Drugs and Medical Devices. International Statistical Classification of Diseases, German Modification. 2022. https:\/\/www.bfarm.de\/EN\/Code-systems\/Classifications\/ICD\/ICD-10-GM\/_node.html. Accessed 2023 Sept 13"},{"key":"1172_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.23736\/S0392-0488.18.05753-X","volume":"155","author":"I Marcian\u00f2","year":"2020","unstructured":"Marcian\u00f2 I, Randazzo MP, Panagia P, et al. Real-world use of biological drugs in patients with psoriasis\/psoriatic arthritis: a retrospective, population-based study of years\u00a02010\u20132014 from Southern Italy. G Ital Dermatol Venereol. 2020;155:441\u201351. https:\/\/doi.org\/10.23736\/S0392-0488.18.05753-X.","journal-title":"G Ital Dermatol Venereol"},{"key":"1172_CR14","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/1346-8138.16543","volume":"49","author":"Y Tada","year":"2022","unstructured":"Tada Y, Kim H, Spanopoulos D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: a retrospective claims database study. J Dermatol. 2022;49:1106\u201317. https:\/\/doi.org\/10.1111\/1346-8138.16543.","journal-title":"J Dermatol"},{"key":"1172_CR15","unstructured":"Puig L, Soliman AM, Davis M. Real-world switching and discontinuation patterns for interleukin-inhibitor treatments in patients with moderate to severe psoriasis in Japan; [Poster]. In: 31st Congress of the European Academy of Dermatology and Venerology (EADV 2022), Milan; 2022."},{"key":"1172_CR16","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/bjd.15027","volume":"176","author":"IYK Iskandar","year":"2017","unstructured":"Iskandar IYK, Ashcroft DM, Warren RB, et al. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2017;176:1297\u2013307. https:\/\/doi.org\/10.1111\/bjd.15027.","journal-title":"Br J Dermatol"},{"key":"1172_CR17","doi-asserted-by":"publisher","first-page":"2176708","DOI":"10.1080\/09546634.2023.2176708","volume":"34","author":"S Thai","year":"2023","unstructured":"Thai S, Zhuo J, Zhong Y, et al. Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies. J Dermatol Treat. 2023;34:2176708. https:\/\/doi.org\/10.1080\/09546634.2023.2176708.","journal-title":"J Dermatol Treat"},{"key":"1172_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2217\/cer-2020-0045","volume":"9","author":"JJ Wu","year":"2020","unstructured":"Wu JJ, Pelletier C, Ung B, Tian M, Khilfeh I, Curtis JR. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics. J Comp Eff Res. 2020;9:767\u201379. https:\/\/doi.org\/10.2217\/cer-2020-0045.","journal-title":"J Comp Eff Res"},{"key":"1172_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/jdv.16803","volume":"35","author":"A Al-Hammadi","year":"2021","unstructured":"Al-Hammadi A, Ruszczak Z, Magari\u00f1os G, Chu C-Y, El Dershaby Y, Tarcha N. Intermittent use of biologic agents for the treatment of psoriasis in adults. J Eur Acad Dermatol Venereol. 2021;35:360\u20137. https:\/\/doi.org\/10.1111\/jdv.16803.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01172-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01172-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01172-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T13:05:48Z","timestamp":1718197548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01172-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01172-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"28 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andreas Pinter is an employee of the Department of Dermatology of the University of Frankfurt, Germany. He has received lecture fees and advisory board fees from AbbVie, Almirall-Hermal, Amgen, Biogen Idec, Biontec, BMS, Boehringer-Ingelheim, Celgene, Celltrion, GSK, Eli-Lilly, Eva Pharma, Galderma, Hexal, Janssen, Klinge Pharma, LEO-Pharma, MC2, Medac, Merck Serono, Mitsubishi, Moonlake, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi-Genzyme, Schering-Plough, UCB Pharma and Zuellig Pharma. Ahmed M. Soliman is an employee of AbbVie Inc. and may hold AbbVie stock, stock options, and\/or patents. AbbVie Inc. sponsored the study, contributed to the design, and participated in the interpretation of data. Karina C. Manz, Valeria Weber, Anja Mocek, and Ariane H\u00f6er are employees of the IGES Institut GmbH, which is a paid consultant of AbbVie Inc. for designing the study, carrying out the analyses, and interpreting the results. Paul Ludwig is an employee of the InGef Institute for Applied Health Research Berlin GmbH, which was contracted and reimbursed by IGES Institut GmbH for providing the data and carrying out the analyses. Mark G. Lebwohl is an employee of the Icahn School of Medicine at Mount Sinai, New York, USA. He has received research funds from Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB, Inc., and is aconsultant for Aditum Bio, Almirall, AltruBio Inc., AnaptysBio, Arcutis, Inc., Aristea Therapeutics, Avotres Therapeutics, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dr. Reddy, EPI, Evommune, Inc., Facilitatation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Helsinn, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, Strata, Trevi, and Verrica.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Since all patient-level data in the database are anonymized to comply with German data protections regulations and German federal law, approval of an ethics committee was not required. The research was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}